A T-cell-engaging antibody for acute lymphoblastic leukaemia
Blinatumomab
An immunotherapy used to treat B-cell acute lymphoblastic leukaemia, given as a continuous drip into a vein.
What is Blinatumomab?
Blinatumomab is a specialist immunotherapy used to treat B-cell acute lymphoblastic leukaemia, a type of blood cancer. It works by linking the body's own immune T-cells to the leukaemia cells so the immune system can destroy them. It is given as a continuous drip into a vein over a long period using a small pump, started in hospital under close monitoring. Its most important risks are cytokine release syndrome, a strong immune reaction, and serious nervous-system effects such as confusion or seizures, both of which need close hospital monitoring, especially when treatment starts.
Education and reference only. This is a plain-language guide to Blinatumomab — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Blinatumomab is a type of immunotherapy known as a bispecific T-cell engager. It is used to treat B-cell acute lymphoblastic leukaemia, a fast-growing blood cancer, including situations where the disease has come back or has not responded to earlier treatment. Rather than being a traditional chemotherapy, it harnesses the patient's own immune cells to attack the cancer. It is given as a continuous infusion into a vein, run slowly over days using a small portable pump, with the first part of treatment started in hospital so that early reactions can be watched for and managed.
How it works
Blinatumomab has two ends: one grabs hold of a marker called CD19 on the surface of the leukaemia cells, and the other grabs hold of the body's immune T-cells. By bringing the two together, it directs the T-cells to recognise and kill the leukaemia cells. Because it must keep the immune cells and cancer cells connected, it is given as a continuous drip rather than a quick dose. When the immune system is switched on strongly in this way, it can cause reactions such as cytokine release syndrome and nervous-system effects, which is why careful monitoring is so important, especially at the start.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist immunotherapy used in the UK to treat a type of blood cancer called B-cell acute lymphoblastic leukaemia, given as a continuous drip in hospital.
Practical use
How to take Blinatumomab
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as a continuous drip into a vein through a small pump over a long period, started in hospital.
- Stay in close contact with your team and attend all monitoring, especially at the start of each cycle when reactions are most likely.
- Report any fever, chills, dizziness or breathing problems straight away, as these can be signs of cytokine release syndrome.
- Report any confusion, trouble speaking, shaking, unsteadiness or fits at once, and avoid driving until your team says it is safe.
- Look after your line and pump as instructed, and do not stop or change the infusion yourself.
Weighing it up
Advantages & disadvantages of Blinatumomab
Advantages
- Uses the body's own immune cells to target B-cell acute lymphoblastic leukaemia.
- Offers a treatment option when the leukaemia has come back or not responded to earlier therapy.
- Works in a different way from traditional chemotherapy.
Disadvantages
- Can cause cytokine release syndrome, a strong and potentially serious immune reaction.
- Can cause serious nervous-system effects such as confusion, unsteadiness or seizures.
- Must be given as a continuous drip through a pump over days, with close hospital monitoring at the start.
Practical use
Good to know
The two most important things to understand are the reactions that come from strongly switching on the immune system. The first is cytokine release syndrome, where a flood of immune signals can cause fever, low blood pressure and breathing problems, usually early in treatment; the team monitors closely and may slow or pause the infusion and give other medicines. The second is serious nervous-system effects, such as confusion, difficulty speaking, tremor, unsteadiness or seizures, which is why treatment is started in hospital and why you should report any such changes at once and avoid driving until advised. Because it is a continuous drip given through a pump over days, looking after the line and pump and keeping in close contact with the team is part of treatment. Steroids or other medicines are often given to reduce reactions, and infections still need prompt attention.
Who should not take it / use with caution
- People who have had a serious allergic reaction to blinatumomab should not receive it.
- It is not used in pregnancy because it can harm an unborn baby, and breastfeeding is avoided.
- It is used with particular caution, and close monitoring, in people with a history of nervous-system problems such as seizures.
Monitoring
- Close monitoring for cytokine release syndrome and nervous-system effects, especially at the start of treatment.
- Regular blood counts and checks of blood chemistry during treatment.
- Watching for signs of infection and reviewing how the leukaemia is responding.
Side effects
- Cytokine release syndrome, with fever, chills, low blood pressure or breathing problems, usually early in treatment.
- Nervous-system effects such as confusion, tremor, difficulty speaking, unsteadiness or seizures.
- A fall in blood cells, raising the risk of infection, and infusion-related reactions.
- Headache, tiredness and a raised risk of infections during treatment.
Key interactions
- Starting treatment can briefly affect how the body handles some other medicines, so your team reviews them.
- Live vaccines are generally avoided during treatment because the immune system is affected.
- Medicines that affect the nervous system are reviewed, given the risk of nervous-system effects.
Available as: A solution given as a continuous drip into a vein through a pump in and after hospital.
Answers
Blinatumomab: frequently asked questions
What is blinatumomab used for?
It is an immunotherapy used to treat B-cell acute lymphoblastic leukaemia, a type of blood cancer, including when it has come back or not responded to other treatment.
How does it work?
It links the body's own immune T-cells to the leukaemia cells so that the immune system can recognise and destroy the cancer.
Why is it given as a continuous drip?
It must keep the immune cells and cancer cells connected to work, so it is given slowly and continuously through a small pump over days rather than as a quick dose.
What is cytokine release syndrome?
It is a strong immune reaction that can cause fever, low blood pressure and breathing problems, usually early in treatment, which the team watches for and manages closely.
Why might it affect my brain or nerves?
Strongly switching on the immune system can cause nervous-system effects such as confusion, unsteadiness or seizures, so report any such changes at once and avoid driving until advised.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.